article
Using virtual screening to identify coronavirus treatments
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
List view / Grid view
Hit-to-Lead
news
Antibacterial cannabinoid compound identified by researchers
A study has revealed that the compound cannabigerol (CBG) is effective as an antibacterial in mice, by preventing bacteria from forming biofilms.
webinar
2020: Reset your expectation for surface plasmon resonance (SPR)
25 February 2020 | By Bruker Daltonics
Learn about the latest software tools for Bruker Daltonic’s SPR instrumentation and explore high-throughput screening strategies enabled by their ecosystem.
news
Utrophin as a novel therapeutic approach for Duchenne muscular dystrophy
Upregulating utrophin using small molecules could be a new therapeutic approach for Duchenne muscular dystrophy (DMD).
news
Novel technique creates complex synthetic drug molecules
A new method has been developed by researchers to create synthetic molecules which replicate natural structures and have potential medicinal uses.
whitepaper
Application note: See what’s really in your formulation with backgrounded membrane imaging
Backgrounded Membrane Imaging (BMI), used by the HORIZON® particle analysis system, performs measurements of subvisible protein aggregates.
whitepaper
Application note: Low volume, high-throughput subvisible AAV aggregate analysis with Horizon
Are you missing the bigger picture with your AAV analytics? Subvisible particle analysis should not require millilitres of precious sample.
news
Screening platform reveals compounds that protect neuronal mitochondria
Researchers have developed a screening system and identified a set of compounds that protect neuronal mitochondria in mice.
news
Assay for reading six molecular pathways simultaneously developed
Researchers have developed a luciferase assay that can be used to monitor the effects of treatments on six different molecular targets at once.
article
Transitioning novel peptide hits into lead compounds
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
article
Hit-to-lead in neglected diseases – it’s a numbers game
The hit-to-lead journey can be a long endeavour, with many failures along the way. Nikki Withers spoke with DNDi ’s Discovery Director Dr Charles Mowbray to hear how the organisation is working to identify new leads with activity in animal models of neglected tropical diseases and the potential for further…
article
Hit-To-Lead In-Depth Focus 2019
This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits into lead compounds.
article
Drug Target Review – Issue 4 2019
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
video
Video: Large-scale hiPSC-based drug development
From small-scale stem cell production to large-scale hiPSC-based drug development: The flexibility of stirred-tank bioreactors.
whitepaper
Application note: Automated NGS library preparation on CyBio FeliX
The CyBio FeliX pipetting system was used to perform all liquid handling steps of the library preparation workflow for personal genome analysis.
